WallStreetZenWallStreetZen

NYSE: CRL
Charles River Laboratories International Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CRL

Based on 12 analysts offering 12 month price targets for Charles River Laboratories International Inc

Min Forecast
$145.00+36.73%
Avg Forecast
$188.67+77.9%
Max Forecast
$250.00+135.74%

Should I buy or sell CRL stock?

Based on 12 analysts offering ratings for Charles River Laboratories International Inc.

Hold
Strong Buy
1 analysts 8.33%
Buy
0 analysts 0%
Hold
11 analysts 91.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Hold" rating. Learn More

Be the first to know when Wall Street analysts revise their CRL stock forecasts and price targets.

CRL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-10
lockedlocked$00.00+00.00%2025-04-09
lockedlocked$00.00+00.00%2025-03-21
lockedlocked$00.00+00.00%2025-03-04
lockedlocked$00.00+00.00%2025-02-20
Baird
Top 30%
71
HoldMaintains$173.00+63.13%2025-02-20
Morgan Stanley
Top 6%
95
HoldMaintains$184.00+73.50%2025-02-05
UBS
Top 9%
92
HoldDowngrades$185.00+74.45%2025-01-17
Bank of America
Top 9%
92
HoldMaintains$210.00+98.02%2024-12-13
TD Cowen
Bottom 7%
7
HoldMaintains$227.00+114.05%2024-11-11

1 of 2

Forecast return on equity

Is CRL forecast to generate an efficient return?

Company
16.62%
Industry
-10.5%
Market
61.97%
CRL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CRL forecast to generate an efficient return on assets?

Company
7.64%
Industry
12.56%
CRL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CRL earnings per share forecast

What is CRL's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$9.32+4,559.4%
Avg 2 year Forecast
$10.10+4,949.35%
Avg 3 year Forecast
$11.25+5,523.75%
CRL's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

CRL revenue forecast

What is CRL's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$3.8B-5.73%
Avg 2 year Forecast
$4.0B-1.1%
Avg 3 year Forecast
$4.3B+5.34%
CRL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CRL earnings growth forecast

How is CRL forecast to perform vs Diagnostics & Research companies and vs the US market?

Company
614.29%
Industry
29.98%
Market
23.64%
CRL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
CRL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
CRL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

CRL revenue growth forecast

How is CRL forecast to perform vs Diagnostics & Research companies and vs the US market?

Company
-0.27%
Industry
5.29%
Market
10.7%
CRL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CRL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CRL vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
CRL$106.05$188.67+77.90%Hold
GH$44.97$53.07+18.01%Strong Buy
RDNT$49.78$69.75+40.12%Strong Buy
EXAS$41.58$68.95+65.82%Strong Buy
SHC$10.48$16.33+55.85%Strong Buy
View Top Diagnostic & Research Stocks

Charles River Laboratories International Stock Forecast FAQ

Is Charles River Laboratories International Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 12 Wall Street analysts covering (NYSE: CRL) stock is to Hold CRL stock.

Out of 12 analysts, 1 (8.33%) are recommending CRL as a Strong Buy, 0 (0%) are recommending CRL as a Buy, 11 (91.67%) are recommending CRL as a Hold, 0 (0%) are recommending CRL as a Sell, and 0 (0%) are recommending CRL as a Strong Sell.

If you're new to stock investing, here's how to buy Charles River Laboratories International stock.

What is CRL's earnings growth forecast for 2025-2027?

(NYSE: CRL) Charles River Laboratories International's forecast annual earnings growth rate of 614.29% is forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 29.98%, and it is also forecast to beat the US market's average forecast earnings growth rate of 23.64%.

Charles River Laboratories International's earnings in 2025 is $10,297,000.On average, 8 Wall Street analysts forecast CRL's earnings for 2025 to be $476,578,407, with the lowest CRL earnings forecast at $467,434,288, and the highest CRL earnings forecast at $485,333,850. On average, 8 Wall Street analysts forecast CRL's earnings for 2026 to be $516,463,747, with the lowest CRL earnings forecast at $484,285,447, and the highest CRL earnings forecast at $543,123,866.

In 2027, CRL is forecast to generate $575,215,225 in earnings, with the lowest earnings forecast at $552,840,772 and the highest earnings forecast at $603,982,379.

What is CRL's revenue growth forecast for 2025-2027?

(NYSE: CRL) Charles River Laboratories International's forecast annual revenue growth rate of -0.27% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.7%.

Charles River Laboratories International's revenue in 2025 is $4,049,989,000.On average, 6 Wall Street analysts forecast CRL's revenue for 2025 to be $195,260,189,774, with the lowest CRL revenue forecast at $194,945,668,891, and the highest CRL revenue forecast at $195,925,490,940. On average, 6 Wall Street analysts forecast CRL's revenue for 2026 to be $204,836,302,260, with the lowest CRL revenue forecast at $194,968,171,198, and the highest CRL revenue forecast at $209,740,015,247.

In 2027, CRL is forecast to generate $218,188,353,016 in revenue, with the lowest revenue forecast at $214,099,223,545 and the highest revenue forecast at $222,935,879,535.

What is CRL's forecast return on assets (ROA) for 2025-2027?

(NYSE: CRL) forecast ROA is 7.64%, which is lower than the forecast US Diagnostics & Research industry average of 12.56%.

What is CRL's Price Target?

According to 12 Wall Street analysts that have issued a 1 year CRL price target, the average CRL price target is $188.67, with the highest CRL stock price forecast at $250.00 and the lowest CRL stock price forecast at $145.00.

On average, Wall Street analysts predict that Charles River Laboratories International's share price could reach $188.67 by Apr 10, 2026. The average Charles River Laboratories International stock price prediction forecasts a potential upside of 77.9% from the current CRL share price of $106.05.

What is CRL's Earnings Per Share (EPS) forecast for 2025-2027?

(NYSE: CRL) Charles River Laboratories International's current Earnings Per Share (EPS) is $0.20. On average, analysts forecast that CRL's EPS will be $9.32 for 2025, with the lowest EPS forecast at $9.14, and the highest EPS forecast at $9.49. On average, analysts forecast that CRL's EPS will be $10.10 for 2026, with the lowest EPS forecast at $9.47, and the highest EPS forecast at $10.62. In 2027, CRL's EPS is forecast to hit $11.25 (min: $10.81, max: $11.81).

What is CRL's forecast return on equity (ROE) for 2025-2027?

(NYSE: CRL) forecast ROE is 16.62%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.